Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
Get valuable insight on select drug products and medically-relevant topics, courtesy of the pharmaceutical industry.
The U.S. Drug Enforcement Administration (DEA) announced it will publish the Final Rule moving hydrocodone combination products (HCPs) from Schedule III to Schedule II tomorrow in the Federal Register.
Mylan announced it has received final approval for its Abbreviated New Drug Application (ANDA) for Dexmedetomidine HCl Injection, the generic version of Hospira's Precedex.
Discussing end-of-life issues and palliative care options with patients who have life-limiting illnesses is challenging. ...
Clinical review - Low back pain
This program will discuss the causes of chronic pain as well as pharmacological options for ...